Mayne Pharma Group（MAYN.F）株式概要メーン・ファーマ・グループは、オーストラリア、ニュージーランド、米国、カナダ、欧州、アジア、そして国際的にブランド医薬品およびジェネリック医薬品を製造・販売しているスペシャリティ・ファーマである。 詳細MAYN.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より90.7%で取引されている 過去5年間の収益は年間12.6%増加しました。 リスク分析株式の流動性は非常に低い 現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るMAYN.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.4083.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-300m561m2016201920222025202620282031Revenue AU$431.1mEarnings AU$63.0mAdvancedSet Fair ValueView all narrativesMayne Pharma Group Limited 競合他社Verrica PharmaceuticalsSymbol: NasdaqCM:VRCAMarket cap: US$101.4mRafael HoldingsSymbol: NYSE:RFLMarket cap: US$69.2mJourney MedicalSymbol: NasdaqCM:DERMMarket cap: US$169.9mCumberland PharmaceuticalsSymbol: NasdaqGS:CPIXMarket cap: US$82.9m価格と性能株価の高値、安値、推移の概要Mayne Pharma Group過去の株価現在の株価AU$1.4052週高値AU$4.0052週安値AU$1.40ベータ1.041ヶ月の変化-20.45%3ヶ月変化-24.53%1年変化-50.88%3年間の変化-40.93%5年間の変化-75.43%IPOからの変化-84.95%最新ニュースお知らせ • Feb 25+ 2 more updatesMayne Pharma Group Limited Announces CEO ChangesMayne Pharma Group Limited announced that on 20 February 2026 (US time) Mr. Shawn Patrick O'Brien stepped down as Chief Executive Officer, and Mr. Aaron Gray, currently Mayne Pharma's Chief Financial Officer, was appointed Chief Executive Officer. Mr. O'Brien joined Mayne Pharma as CEO and Managing Director in October 2022 and will remain available to the Board in an advisory capacity until May 1, 2026 to support an orderly transition to Mr. Aaron Gray as part of Mayne Pharma's structured succession process. Aaron Gray joined Mayne Pharma in July 2022 and has been the Chief Financial Officer since August 29, 2022. He brings over 20 years of experience to the role. Prior to joining Mayne Pharma, Aaron held senior finance roles at Siemens Healthineers, a leading global medical technology company with EUR20 billion in revenues and 48,000 employees globally. Most recently, he was Senior Vice President, USA Customer Finance with EUR5 billion in revenues. Prior to joining Siemens Healthineers, he spent 15 years in finance roles at Siemens AG energy divisions. Aaron has significant expertise in the areas of financial planning and analysis, strategy, digitisation, sales operations, manufacturing, risk management and operational excellence.お知らせ • Feb 19Mayne Pharma Group Limited to Report First Half, 2026 Results on Feb 23, 2026Mayne Pharma Group Limited announced that they will report first half, 2026 results on Feb 23, 2026お知らせ • Jan 15Mayne Pharma Receives Notice of Appeal Filed by Cosette and Its Bidco with the Supreme Court of New South Wales, Court of AppealMayne Pharma Group Limited refers to its announcement on 16 October 2025 relating to the judgment delivered on 15 October 2025 in which the Supreme Court of New South Wales found in favour of Mayne Pharma and its announcement on 10 November 2025 regarding a notice of intention to appeal filed by Cosette Pharmaceuticals Inc. (Cosette) and its BidCo. Mayne Pharma has received a notice of appeal filed by Cosette and its BidCo with the Supreme Court of New South Wales, Court of Appeal. The two grounds set out in the notice of appeal seek to challenge various of the Court's findings related to: Mayne Pharma's FY25 EBITDA the subject of Cosette's misleading and deceptive conduct claim; and Cosette's allegation that a Mayne Material Adverse Change had occurred on the basis of Cosette's pleaded Third Quarter FY25 Sales Performance Matters.お知らせ • Jan 14Mayne Pharma Group Limited Announces Board Changes Effective January 14, 2026Mayne Pharma Group Limited announced that the Board of Directors has decided to reduce the size of the Board. Mr. Frank Condella, Board Chair, will retire from the Board effective January 14, 2026. Mr. Condella has served as a director of Mayne Pharma since May 2018 and as Board Chair since September 2021. Non-Executive directors Mr. Patrick Blake and Mrs. Anne Lockwood will step down from the Board following the release of the Company’s half year results in February 2026 to focus on other opportunities. Mr. Blake has served as a director since June 2018. Mrs. Lockwood has served as a director since November 2023. Professor Bruce Robinson has been appointed as Non-Executive Chair of the Board effective January 14, 2026. Professor Robinson was appointed a Non-Executive Director of the Company in August 2014. He is a Non-Executive Director of Cochlear Limited and CS Pharmaceuticals Limited. He is formerly a Board Member of the Woolcock Institute, was Chair of the National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Professor Robinson is Chair of the Science, Technology and Medical Committee and a member of the Nomination Committee.お知らせ • Dec 22Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026. Location: minter ellison office, level 20, collins arch, 447 collins st, and, melbourne Australiaお知らせ • Aug 01Mayne Pharma Group Limited to Report Fiscal Year 2025 Results on Aug 29, 2025Mayne Pharma Group Limited announced that they will report fiscal year 2025 results on Aug 29, 2025最新情報をもっと見るRecent updatesお知らせ • Feb 25+ 2 more updatesMayne Pharma Group Limited Announces CEO ChangesMayne Pharma Group Limited announced that on 20 February 2026 (US time) Mr. Shawn Patrick O'Brien stepped down as Chief Executive Officer, and Mr. Aaron Gray, currently Mayne Pharma's Chief Financial Officer, was appointed Chief Executive Officer. Mr. O'Brien joined Mayne Pharma as CEO and Managing Director in October 2022 and will remain available to the Board in an advisory capacity until May 1, 2026 to support an orderly transition to Mr. Aaron Gray as part of Mayne Pharma's structured succession process. Aaron Gray joined Mayne Pharma in July 2022 and has been the Chief Financial Officer since August 29, 2022. He brings over 20 years of experience to the role. Prior to joining Mayne Pharma, Aaron held senior finance roles at Siemens Healthineers, a leading global medical technology company with EUR20 billion in revenues and 48,000 employees globally. Most recently, he was Senior Vice President, USA Customer Finance with EUR5 billion in revenues. Prior to joining Siemens Healthineers, he spent 15 years in finance roles at Siemens AG energy divisions. Aaron has significant expertise in the areas of financial planning and analysis, strategy, digitisation, sales operations, manufacturing, risk management and operational excellence.お知らせ • Feb 19Mayne Pharma Group Limited to Report First Half, 2026 Results on Feb 23, 2026Mayne Pharma Group Limited announced that they will report first half, 2026 results on Feb 23, 2026お知らせ • Jan 15Mayne Pharma Receives Notice of Appeal Filed by Cosette and Its Bidco with the Supreme Court of New South Wales, Court of AppealMayne Pharma Group Limited refers to its announcement on 16 October 2025 relating to the judgment delivered on 15 October 2025 in which the Supreme Court of New South Wales found in favour of Mayne Pharma and its announcement on 10 November 2025 regarding a notice of intention to appeal filed by Cosette Pharmaceuticals Inc. (Cosette) and its BidCo. Mayne Pharma has received a notice of appeal filed by Cosette and its BidCo with the Supreme Court of New South Wales, Court of Appeal. The two grounds set out in the notice of appeal seek to challenge various of the Court's findings related to: Mayne Pharma's FY25 EBITDA the subject of Cosette's misleading and deceptive conduct claim; and Cosette's allegation that a Mayne Material Adverse Change had occurred on the basis of Cosette's pleaded Third Quarter FY25 Sales Performance Matters.お知らせ • Jan 14Mayne Pharma Group Limited Announces Board Changes Effective January 14, 2026Mayne Pharma Group Limited announced that the Board of Directors has decided to reduce the size of the Board. Mr. Frank Condella, Board Chair, will retire from the Board effective January 14, 2026. Mr. Condella has served as a director of Mayne Pharma since May 2018 and as Board Chair since September 2021. Non-Executive directors Mr. Patrick Blake and Mrs. Anne Lockwood will step down from the Board following the release of the Company’s half year results in February 2026 to focus on other opportunities. Mr. Blake has served as a director since June 2018. Mrs. Lockwood has served as a director since November 2023. Professor Bruce Robinson has been appointed as Non-Executive Chair of the Board effective January 14, 2026. Professor Robinson was appointed a Non-Executive Director of the Company in August 2014. He is a Non-Executive Director of Cochlear Limited and CS Pharmaceuticals Limited. He is formerly a Board Member of the Woolcock Institute, was Chair of the National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Professor Robinson is Chair of the Science, Technology and Medical Committee and a member of the Nomination Committee.お知らせ • Dec 22Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026. Location: minter ellison office, level 20, collins arch, 447 collins st, and, melbourne Australiaお知らせ • Aug 01Mayne Pharma Group Limited to Report Fiscal Year 2025 Results on Aug 29, 2025Mayne Pharma Group Limited announced that they will report fiscal year 2025 results on Aug 29, 2025お知らせ • Apr 10TherapeuticsMD, Inc. Files Lawsuit Against Mayne Pharma for Contract BreachesOn April 8, 2025, TherapeuticsMD Inc., a Nevada corporation (the “Company”), filed a lawsuit against Mayne Pharma LLC (“Mayne Pharma”) in the United States District Court for the District of Delaware (the “Mayne Lawsuit”) seeking damages for breach of contract, breach of the implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to Mayne Pharma’s actions in relation to the License Agreement, dated December 4, 2022, as amended, between the Company and Mayne Pharma and the Transaction Agreement, dated December 4, 2022, as amended, between the Company and Mayne Pharma. The Mayne Lawsuit primarily pertains to the previously disclosed disputes between the Company and Mayne Pharma relating to certain net working capital allowances and certain actions or inactions by Mayne Pharma relating thereto. The Mayne Lawsuit is TherapeuticsMD Inc. v. Mayne Pharma LLC, Case No. not assigned (D. Del.).お知らせ • Feb 22Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million.Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million on February 20, 2025. A cash consideration of AUD 601.22 million valued at AUD 7.4 per share will be paid by Cosette Pharmaceuticals, Inc. As part of consideration, AUD 601.22 million is paid towards common equity of Mayne Pharma Group Limited. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders and subject to court approval. The deal has been unanimously approved by the board. The expected completion of the transaction is May 21, 2025 to June 10, 2025. Jefferies Pty Ltd acted as financial advisor for Mayne Pharma Group Limited. Arnold & Porter Kaye Scholer LLP acted as legal advisor for Mayne Pharma Group Limited. Gilbert and Tobin acted as legal advisor for Mayne Pharma Group Limited. Ropes & Gray LLP acted as legal advisor for Cosette Pharmaceuticals, Inc. Corrs Chambers Westgarth acted as legal advisor for Cosette Pharmaceuticals, Inc. UBS Securities LLC acted as financial advisor for Cosette Pharmaceuticals, Inc. Santander US Capital Markets LLC acted as financial advisor for Cosette Pharmaceuticals, Inc.お知らせ • Feb 10+ 1 more updateMayne Pharma Group Limited Provides Earnings Guidance for the First Half Ended 31 December 2024Mayne Pharma Group Limited provided earnings guidance for the first half ended 31 December 2024. For the period, the company expects revenues to be $210 million to $215 million, reflecting 12 - 14% growth on first half of 2024.お知らせ • Feb 21+ 1 more updateMayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024Mayne Pharma Group Limited announced that they will report fiscal year 2024 results on Aug 23, 2024お知らせ • Feb 12Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024Mayne Pharma Group Limited announced that they will report first half, 2024 results on Feb 26, 2024お知らせ • Nov 30Mayne Pharma Group Limited Approves Election of Anne LockwoodMayne Pharma Group Limited at its AGM approved election of Anne Lockwood.お知らせ • Oct 27Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023, at 10:00 AUS Eastern Standard Time. Location: MinterEllison Offices, Lvl 20, Collins Arch, 447 Collins St Melbourne Australia Agenda: To consider and approve the statutory reports for the financial year ended 30 June 2023; to consider and approve the election of Director; to consider and approve the remuneration report; to consider and approve the Short-Term Incentive grant of Restricted Stock Unit Performance Rights and a Long-Term Incentive grant of Performance Rights to the CEO and Managing Director; to consider and approve the appointment of BDO Audit Pty Ltd as the Company's auditor; and to consider and approve the extension of the on-market share buy-back.お知らせ • Aug 24Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Mayne Pharma Group Limited announced that they will report fiscal year 2023 results on Aug 31, 2023お知らせ • Jul 27Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023Mayne Pharma Group Limited announced that Dr. Carolyn Myers will retire from the Board at the end of July 2023.Dr Myers has served as a Director of Mayne Pharma since October 2021. She was appointed to theBoard after being nominated by Mithra Pharmaceuticals SA under the terms of the license andsupply agreement to commercialise NEXTSTELLIS® (E4/DRSP) oral contraceptive in the UnitedStates.お知らせ • Feb 15+ 1 more updateMayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023Mayne Pharma Group Limited announced that they will report first half, 2023 results on Feb 28, 2023お知らせ • Jan 14Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of NuvaringMayne Pharma Group Limited and Mithra Pharmaceuticals, SA announced the launch of HALOETTE (etonogestrel and ethinyl estradiol) a vaginal hormonal contraceptive ring into the US market. HALOETTE contraceptive is a generic version of NUVARING, a combined hormonal contraceptive flexible ring indicated for the prevention of pregnancy. Under the terms of the long-term license and supply agreement, Mayne Pharma will pay Mithra a milestone of EUR 1.6 million.株主還元MAYN.FUS PharmaceuticalsUS 市場7D-18.1%1.9%-0.8%1Y-50.9%41.8%27.1%株主還元を見る業界別リターン: MAYN.F過去 1 年間で41.8 % の収益を上げたUS Pharmaceuticals業界を下回りました。リターン対市場: MAYN.Fは、過去 1 年間で27.1 % のリターンを上げたUS市場を下回りました。価格変動Is MAYN.F's price volatile compared to industry and market?MAYN.F volatilityMAYN.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.0%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%安定した株価: MAYN.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のMAYN.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2005491Aaron Graywww.maynepharma.comスペシャリティファーマであるメーン・ファーマ・グループ・リミテッドは、オーストラリア、ニュージーランド、米国、カナダ、欧州、アジア、そして国際的にブランド医薬品およびジェネリック医薬品を製造・販売している。同社は3つのセグメントで事業を展開している：ウィメンズヘルス、皮膚科、インターナショナル。経口薬物送達システム、開発・製造受託サービスを第三者顧客に提供するほか、皮膚科、ウィメンズヘルス、感染症治療領域の特殊医薬品を販売している。前身はHalcygen Pharmaceuticals Limitedで、2010年11月に社名をMayne Pharma Group Limitedに変更。2005年に法人化され、オーストラリアのソールズベリー・サウスに本社を置いている。もっと見るMayne Pharma Group Limited 基礎のまとめMayne Pharma Group の収益と売上を時価総額と比較するとどうか。MAYN.F 基礎統計学時価総額US$137.10m収益（TTM）-US$58.78m売上高(TTM)US$291.11m0.5xP/Sレシオ-2.3xPER（株価収益率MAYN.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MAYN.F 損益計算書（TTM）収益AU$407.11m売上原価AU$152.12m売上総利益AU$254.99mその他の費用AU$337.20m収益-AU$82.20m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-1.01グロス・マージン62.64%純利益率-20.19%有利子負債／自己資本比率10.5%MAYN.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 19:43終値2026/05/20 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mayne Pharma Group Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関William DunlopBofA Global ResearchElyse ShapiroCanaccord GenuityJohn Deakin-BellCitigroup Inc2 その他のアナリストを表示
お知らせ • Feb 25+ 2 more updatesMayne Pharma Group Limited Announces CEO ChangesMayne Pharma Group Limited announced that on 20 February 2026 (US time) Mr. Shawn Patrick O'Brien stepped down as Chief Executive Officer, and Mr. Aaron Gray, currently Mayne Pharma's Chief Financial Officer, was appointed Chief Executive Officer. Mr. O'Brien joined Mayne Pharma as CEO and Managing Director in October 2022 and will remain available to the Board in an advisory capacity until May 1, 2026 to support an orderly transition to Mr. Aaron Gray as part of Mayne Pharma's structured succession process. Aaron Gray joined Mayne Pharma in July 2022 and has been the Chief Financial Officer since August 29, 2022. He brings over 20 years of experience to the role. Prior to joining Mayne Pharma, Aaron held senior finance roles at Siemens Healthineers, a leading global medical technology company with EUR20 billion in revenues and 48,000 employees globally. Most recently, he was Senior Vice President, USA Customer Finance with EUR5 billion in revenues. Prior to joining Siemens Healthineers, he spent 15 years in finance roles at Siemens AG energy divisions. Aaron has significant expertise in the areas of financial planning and analysis, strategy, digitisation, sales operations, manufacturing, risk management and operational excellence.
お知らせ • Feb 19Mayne Pharma Group Limited to Report First Half, 2026 Results on Feb 23, 2026Mayne Pharma Group Limited announced that they will report first half, 2026 results on Feb 23, 2026
お知らせ • Jan 15Mayne Pharma Receives Notice of Appeal Filed by Cosette and Its Bidco with the Supreme Court of New South Wales, Court of AppealMayne Pharma Group Limited refers to its announcement on 16 October 2025 relating to the judgment delivered on 15 October 2025 in which the Supreme Court of New South Wales found in favour of Mayne Pharma and its announcement on 10 November 2025 regarding a notice of intention to appeal filed by Cosette Pharmaceuticals Inc. (Cosette) and its BidCo. Mayne Pharma has received a notice of appeal filed by Cosette and its BidCo with the Supreme Court of New South Wales, Court of Appeal. The two grounds set out in the notice of appeal seek to challenge various of the Court's findings related to: Mayne Pharma's FY25 EBITDA the subject of Cosette's misleading and deceptive conduct claim; and Cosette's allegation that a Mayne Material Adverse Change had occurred on the basis of Cosette's pleaded Third Quarter FY25 Sales Performance Matters.
お知らせ • Jan 14Mayne Pharma Group Limited Announces Board Changes Effective January 14, 2026Mayne Pharma Group Limited announced that the Board of Directors has decided to reduce the size of the Board. Mr. Frank Condella, Board Chair, will retire from the Board effective January 14, 2026. Mr. Condella has served as a director of Mayne Pharma since May 2018 and as Board Chair since September 2021. Non-Executive directors Mr. Patrick Blake and Mrs. Anne Lockwood will step down from the Board following the release of the Company’s half year results in February 2026 to focus on other opportunities. Mr. Blake has served as a director since June 2018. Mrs. Lockwood has served as a director since November 2023. Professor Bruce Robinson has been appointed as Non-Executive Chair of the Board effective January 14, 2026. Professor Robinson was appointed a Non-Executive Director of the Company in August 2014. He is a Non-Executive Director of Cochlear Limited and CS Pharmaceuticals Limited. He is formerly a Board Member of the Woolcock Institute, was Chair of the National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Professor Robinson is Chair of the Science, Technology and Medical Committee and a member of the Nomination Committee.
お知らせ • Dec 22Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026. Location: minter ellison office, level 20, collins arch, 447 collins st, and, melbourne Australia
お知らせ • Aug 01Mayne Pharma Group Limited to Report Fiscal Year 2025 Results on Aug 29, 2025Mayne Pharma Group Limited announced that they will report fiscal year 2025 results on Aug 29, 2025
お知らせ • Feb 25+ 2 more updatesMayne Pharma Group Limited Announces CEO ChangesMayne Pharma Group Limited announced that on 20 February 2026 (US time) Mr. Shawn Patrick O'Brien stepped down as Chief Executive Officer, and Mr. Aaron Gray, currently Mayne Pharma's Chief Financial Officer, was appointed Chief Executive Officer. Mr. O'Brien joined Mayne Pharma as CEO and Managing Director in October 2022 and will remain available to the Board in an advisory capacity until May 1, 2026 to support an orderly transition to Mr. Aaron Gray as part of Mayne Pharma's structured succession process. Aaron Gray joined Mayne Pharma in July 2022 and has been the Chief Financial Officer since August 29, 2022. He brings over 20 years of experience to the role. Prior to joining Mayne Pharma, Aaron held senior finance roles at Siemens Healthineers, a leading global medical technology company with EUR20 billion in revenues and 48,000 employees globally. Most recently, he was Senior Vice President, USA Customer Finance with EUR5 billion in revenues. Prior to joining Siemens Healthineers, he spent 15 years in finance roles at Siemens AG energy divisions. Aaron has significant expertise in the areas of financial planning and analysis, strategy, digitisation, sales operations, manufacturing, risk management and operational excellence.
お知らせ • Feb 19Mayne Pharma Group Limited to Report First Half, 2026 Results on Feb 23, 2026Mayne Pharma Group Limited announced that they will report first half, 2026 results on Feb 23, 2026
お知らせ • Jan 15Mayne Pharma Receives Notice of Appeal Filed by Cosette and Its Bidco with the Supreme Court of New South Wales, Court of AppealMayne Pharma Group Limited refers to its announcement on 16 October 2025 relating to the judgment delivered on 15 October 2025 in which the Supreme Court of New South Wales found in favour of Mayne Pharma and its announcement on 10 November 2025 regarding a notice of intention to appeal filed by Cosette Pharmaceuticals Inc. (Cosette) and its BidCo. Mayne Pharma has received a notice of appeal filed by Cosette and its BidCo with the Supreme Court of New South Wales, Court of Appeal. The two grounds set out in the notice of appeal seek to challenge various of the Court's findings related to: Mayne Pharma's FY25 EBITDA the subject of Cosette's misleading and deceptive conduct claim; and Cosette's allegation that a Mayne Material Adverse Change had occurred on the basis of Cosette's pleaded Third Quarter FY25 Sales Performance Matters.
お知らせ • Jan 14Mayne Pharma Group Limited Announces Board Changes Effective January 14, 2026Mayne Pharma Group Limited announced that the Board of Directors has decided to reduce the size of the Board. Mr. Frank Condella, Board Chair, will retire from the Board effective January 14, 2026. Mr. Condella has served as a director of Mayne Pharma since May 2018 and as Board Chair since September 2021. Non-Executive directors Mr. Patrick Blake and Mrs. Anne Lockwood will step down from the Board following the release of the Company’s half year results in February 2026 to focus on other opportunities. Mr. Blake has served as a director since June 2018. Mrs. Lockwood has served as a director since November 2023. Professor Bruce Robinson has been appointed as Non-Executive Chair of the Board effective January 14, 2026. Professor Robinson was appointed a Non-Executive Director of the Company in August 2014. He is a Non-Executive Director of Cochlear Limited and CS Pharmaceuticals Limited. He is formerly a Board Member of the Woolcock Institute, was Chair of the National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Professor Robinson is Chair of the Science, Technology and Medical Committee and a member of the Nomination Committee.
お知らせ • Dec 22Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026Mayne Pharma Group Limited, Annual General Meeting, Jan 29, 2026. Location: minter ellison office, level 20, collins arch, 447 collins st, and, melbourne Australia
お知らせ • Aug 01Mayne Pharma Group Limited to Report Fiscal Year 2025 Results on Aug 29, 2025Mayne Pharma Group Limited announced that they will report fiscal year 2025 results on Aug 29, 2025
お知らせ • Apr 10TherapeuticsMD, Inc. Files Lawsuit Against Mayne Pharma for Contract BreachesOn April 8, 2025, TherapeuticsMD Inc., a Nevada corporation (the “Company”), filed a lawsuit against Mayne Pharma LLC (“Mayne Pharma”) in the United States District Court for the District of Delaware (the “Mayne Lawsuit”) seeking damages for breach of contract, breach of the implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to Mayne Pharma’s actions in relation to the License Agreement, dated December 4, 2022, as amended, between the Company and Mayne Pharma and the Transaction Agreement, dated December 4, 2022, as amended, between the Company and Mayne Pharma. The Mayne Lawsuit primarily pertains to the previously disclosed disputes between the Company and Mayne Pharma relating to certain net working capital allowances and certain actions or inactions by Mayne Pharma relating thereto. The Mayne Lawsuit is TherapeuticsMD Inc. v. Mayne Pharma LLC, Case No. not assigned (D. Del.).
お知らせ • Feb 22Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million.Cosette Pharmaceuticals, Inc. agreed to acquire Mayne Pharma Group Limited (ASX:MYX) from Viburnum Funds Pty Ltd, Bruce Mathieson and others for approximately AUD 600 million on February 20, 2025. A cash consideration of AUD 601.22 million valued at AUD 7.4 per share will be paid by Cosette Pharmaceuticals, Inc. As part of consideration, AUD 601.22 million is paid towards common equity of Mayne Pharma Group Limited. The transaction is subject to approval by regulatory board / committee, approval of merger agreement by target board, approval of offer by target shareholders and subject to court approval. The deal has been unanimously approved by the board. The expected completion of the transaction is May 21, 2025 to June 10, 2025. Jefferies Pty Ltd acted as financial advisor for Mayne Pharma Group Limited. Arnold & Porter Kaye Scholer LLP acted as legal advisor for Mayne Pharma Group Limited. Gilbert and Tobin acted as legal advisor for Mayne Pharma Group Limited. Ropes & Gray LLP acted as legal advisor for Cosette Pharmaceuticals, Inc. Corrs Chambers Westgarth acted as legal advisor for Cosette Pharmaceuticals, Inc. UBS Securities LLC acted as financial advisor for Cosette Pharmaceuticals, Inc. Santander US Capital Markets LLC acted as financial advisor for Cosette Pharmaceuticals, Inc.
お知らせ • Feb 10+ 1 more updateMayne Pharma Group Limited Provides Earnings Guidance for the First Half Ended 31 December 2024Mayne Pharma Group Limited provided earnings guidance for the first half ended 31 December 2024. For the period, the company expects revenues to be $210 million to $215 million, reflecting 12 - 14% growth on first half of 2024.
お知らせ • Feb 21+ 1 more updateMayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024Mayne Pharma Group Limited announced that they will report fiscal year 2024 results on Aug 23, 2024
お知らせ • Feb 12Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024Mayne Pharma Group Limited announced that they will report first half, 2024 results on Feb 26, 2024
お知らせ • Nov 30Mayne Pharma Group Limited Approves Election of Anne LockwoodMayne Pharma Group Limited at its AGM approved election of Anne Lockwood.
お知らせ • Oct 27Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023, at 10:00 AUS Eastern Standard Time. Location: MinterEllison Offices, Lvl 20, Collins Arch, 447 Collins St Melbourne Australia Agenda: To consider and approve the statutory reports for the financial year ended 30 June 2023; to consider and approve the election of Director; to consider and approve the remuneration report; to consider and approve the Short-Term Incentive grant of Restricted Stock Unit Performance Rights and a Long-Term Incentive grant of Performance Rights to the CEO and Managing Director; to consider and approve the appointment of BDO Audit Pty Ltd as the Company's auditor; and to consider and approve the extension of the on-market share buy-back.
お知らせ • Aug 24Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Mayne Pharma Group Limited announced that they will report fiscal year 2023 results on Aug 31, 2023
お知らせ • Jul 27Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023Mayne Pharma Group Limited announced that Dr. Carolyn Myers will retire from the Board at the end of July 2023.Dr Myers has served as a Director of Mayne Pharma since October 2021. She was appointed to theBoard after being nominated by Mithra Pharmaceuticals SA under the terms of the license andsupply agreement to commercialise NEXTSTELLIS® (E4/DRSP) oral contraceptive in the UnitedStates.
お知らせ • Feb 15+ 1 more updateMayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023Mayne Pharma Group Limited announced that they will report first half, 2023 results on Feb 28, 2023
お知らせ • Jan 14Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of NuvaringMayne Pharma Group Limited and Mithra Pharmaceuticals, SA announced the launch of HALOETTE (etonogestrel and ethinyl estradiol) a vaginal hormonal contraceptive ring into the US market. HALOETTE contraceptive is a generic version of NUVARING, a combined hormonal contraceptive flexible ring indicated for the prevention of pregnancy. Under the terms of the long-term license and supply agreement, Mayne Pharma will pay Mithra a milestone of EUR 1.6 million.
